Investors are betting that the U.S. Food and Drug Administration will break with tradition and approve Dendreon’s prostate cancer treatment. The company’s stock, which traded below $4 in March, soared 30.6% on Monday, to $23.58, a $5.53 gain.>>> Discuss This Story
